CATALOG
SS-31
Mitochondria-targeted tetrapeptide (Forzinity). FDA-approved September 2025 for Barth syndrome—first FDA-approved mitochondria-targeted therapeutic.
HPLC verified purity
COA available by batch
Insured & tracked · $5.99
cGMP Certified
ISO/IEO Accredited
Janoshik Tested
>99%
Purity (HPLC)
Single / Multiple
Vials per Set
1
Strength Options
Full Research Profile
Protocols, clinical evidence, interactions & more on
Pep-Pedia
⚠ For laboratory research use only. Not for human consumption. Must be 18+ to purchase.
Certificate of Analysis
SS-31
Loading document…